SRTPUTL4 ;BIR/SJA - RISK ASSESSMENT UTILITY ;05/15/08
Source file <SRTPUTL4.m>
| Name | Comments | DBIA/ICR reference |
|---|---|---|
| BD | ;;24^Alpha 1 Anti-Trypsin Deficiency^
|
|
| BE | ;;25^Bronchiectasis^
|
|
| BF | ;;26^Glomerular Sclerosis/Nephritis^
|
|
| BG | ;;27^Graft Failure^
|
|
| BA | ;;21^Acute Liver Failure^
|
|
| BB | ;;22^Lung Cancer^
|
|
| BC | ;;23^Alcoholic Cirrhosis^
|
|
| AGG | ;;177^Current Digoxin Use^
|
|
| AGF | ;;176^IV NTG within 48 Hours^
|
|
| AGE | ;;175^Congestive Heart Failure (CHF)^
|
|
| AGD | ;;174^Cerebral Vascular Disease^
|
|
| BH | ;;28^HBV Cirrhosis (Hepatitis B)^
|
|
| BI | ;;29^HCC (Hepatocellular CA)^
|
|
| BJ | ;;20^Acetaminophen Toxicity^
|
|
| AFH | ;;168^PAW Mean Pressure^
|
|
| AGJ | ;;170^Date of Death^
|
|
| AGI | ;;179^Preoperative Circulatory Device^
|
|
| AGH | ;;178^Current Diuretic Use^
|
|
| AFI | ;;169^FEV1 ^
|
|
| ABH | ;;128^Emphysema^
|
|
| D | ;;4^Recipient Height^
|
|
| AGC | ;;173^Number of Prior Heart Surgeries^
|
|
| AGB | ;;172^Prior MI^
|
|
| GG | ;;77^Donor Substance Abuse^
|
|
| GF | ;;76^COPD ^
|
|
| GE | ;;75^Liver Disease^
|
|
| GD | ;;74^Pulmonary Hypertension / Elevated PAP^
|
|
| GC | ;;73^Donor HLA-DR Typing^
|
|
| GB | ;;72^Donor HLA-DQ Typing^
|
|
| GA | ;;71^Elevated PAP^
|
|
| AAA | ;;111^Portal Vein Thrombosis^
|
|
| GJ | ;;70^Donor Date of Birth^
|
|
| GI | ;;79^History of Bleeding Esophageal and/or Gastric Varices^
|
|
| GH | ;;78^Porto Pulmonary Hypertension^
|
|
| AHB | ;;182^Transplant Type^
|
|
| AHA | ;;181^Assessment Status^
|
|
| AHG | ;;187^Date Started Dialysis^
|
|
| AHD | ;;184^Date Transmitted^
|
|
| AHE | ;;185^VA or Non-VA Indicator^
|
|
| AHI | ;;189^Tracheostomy^
|
|
| AFD | ;;164^PVR After Vasodilation^
|
|
| ABB | ;;122^Coma Greater than 24 Hours Postop (Y/N)^
|
|
| HJ | ;;80^Pre-Transplant Malignancy^
|
|
| HH | ;;88^History of Ascites^
|
|
| HI | ;;89^Total Ischemia Time for Organ^
|
|
| AEE | ;;155^Dilated Cardiomyopathy^
|
|
| AED | ;;154^Creatinine on Day of Transplant^
|
|
| AEG | ;;157^Ischemic Cardiomyopathy^
|
|
| AEF | ;;156^Coronary Artery Disease^
|
|
| HB | ;;82^History of Other Pre-Transplant Malignancy^
|
|
| HC | ;;83^Recipient Substance Abuse^
|
|
| HA | ;;81^History of Preop Transplant Skin Malignancy^
|
|
| HF | ;;86^Acute or Chronic Encephalopathy^
|
|
| HG | ;;87^Cold Ischemia Time for Organ^
|
|
| HD | ;;84^Active Infection for PSC^
|
|
| HE | ;;85^Warm Ischemia Time For Organ^
|
|
| ABF | ;;126^Return to Surgery within 30 days^
|
|
| GET | ||
| AFE | ;;165^LVEF % ^
|
|
| ABG | ;;127^Seizures^
|
|
| I | ;;9^IVIG Recipient^
|
|
| ABI | ;;129^Other Diagnosis^
|
|
| AFF | ;;166^PRA %^
|
|
| C | ;;3^VACO ID
|
|
| AFG | ;;167^PA Systolic Pressure^
|
|
| EI | ;;59^Diabetic Retinopathy^
|
|
| EH | ;;58^UNOS Status at time of Listing^
|
|
| AFJ | ;;160^Idiopathic Cardiomyopathy^
|
|
| EJ | ;;50^LAS Score at Listing^
|
|
| EE | ;;55^Biologic MELD score at transplant^
|
|
| ED | ;;54^MELD score at transplant^
|
|
| EG | ;;57^UNOS Status at time of Transplant^
|
|
| EF | ;;56^Bile Leak^
|
|
| EA | ;;51^LAS Score at Transplant^
|
|
| AFA | ;;161^Viral Cardiomyopathy^
|
|
| EC | ;;53^Biologic MELD score at listing^
|
|
| EB | ;;52^MELD Score at Listing^
|
|
| AFB | ;;162^Peripartum Cardiomyopathy^
|
|
| AFC | ;;163^PVR Before Vasodilation^
|
|
| AJH | ;;108^HIV + (positive)^
|
|
| AJI | ;;109^Post Transplant Prophylaxis for CMV/Antiviral Treatment^
|
|
| ACC | ;;133^Graft Failure Date^
|
|
| ACB | ;;132^Peripheral Vascular Disease^
|
|
| ACA | ;;131^Preop Functional Health Status^
|
|
| ACG | ;;137^Pancreatic Duct Anastomosis^
|
|
| ACF | ;;136^C-peptide at Time of Listing^
|
|
| ACE | ;;135^Glucose at Time of Listing^
|
|
| ACD | ;;134^Pancreas^
|
|
| ACJ | ;;130^New Mechanical Circulatory Support^
|
|
| ACI | ;;139^Amylase Post Transplant^
|
|
| ACH | ;;138^Glucose Post Transplant^
|
|
| FA | ;;61^Cardiac Disease (CAD, AF, EF<50%)^
|
|
| FB | ;;62^Inotrope Dependent Pre-Transplant^
|
|
| FC | ;;63^Medical Center Division^
|
|
| FD | ;;64^Donor HLA-A Typing^
|
|
| FE | ;;65^Donor HLA-B Typing^
|
|
| FF | ;;66^Donor HLA-C Typing^
|
|
| FG | ;;67^Donor HLA-BW Typing^
|
|
| FH | ;;68^Crossmatch D/R^
|
|
| FI | ;;69^Deceased Donor^
|
|
| FJ | ;;60^Diabetic Neuropathy^
|
|
| AJC | ;;103^Living Donor^
|
|
| AIJ | ;;190^Mediastinitis^
|
|
| AAC | ;;113^Lung Disease^
|
|
| AJD | ;;104^Donor with Malignancy^
|
|
| AAB | ;;112^Other Cardiomyopathy^
|
|
| AJE | ;;105^Primary Non-Function^
|
|
| AJF | ;;106^Secondary Sclerosing Cholangitis^
|
|
| AAI | ;;119^Cardiac Arrest Requiring CPR^
|
|
| AJG | ;;107^Toxic Exposure^
|
|
| E | ;;5^Recipient Weight^
|
|
| CJ | ;;30^HCV Cirrhosis (Hepatitis C)^
|
|
| CI | ;;39^Primary Sclerosing Cholangitis^
|
|
| CH | ;;38^Primary Biliary Cholangitis^
|
|
| CC | ;;33^Membranous Nephropathy^
|
|
| CB | ;;32^Interstitial Lung Disease^
|
|
| CA | ;;31^Donor Height^
|
|
| CG | ;;37^Polycystic Disease^
|
|
| CF | ;;36^Donor Weight^
|
|
| CE | ;;35^NASH ^
|
|
| CD | ;;34^Metabolic^
|
|
| ADF | ;;146^Transfusion >4 RBC Units^
|
|
| ADG | ;;147^Diabetes Mellitus^
|
|
| ADD | ;;144^PRA at Transplant^
|
|
| ADE | ;;145^Hypertension Requiring Meds^
|
|
| ADB | ;;142^Oral Hypoglycemics Required Post Transplant^
|
|
| ADC | ;;143^PRA at Listing^
|
|
| ADA | ;;141^Insulin Required Post transplant^
|
|
| AAJ | ;;110^Post Transplant Prophylaxis for PCP/Antibacterial Treatment^
|
|
| ADJ | ;;140^Lipase Post Transplant^
|
|
| ADH | ;;148^Reoperation for Bleeding^
|
|
| ADI | ;;149^Amiodarone Use^
|
|
| AEA | ;;151^Hyperlipidemia History^
|
|
| AAH | ;;118^On Ventilator > 48 Hours^
|
|
| AEC | ;;153^Prior Blood Transfusion^
|
|
| AEB | ;;152^Ventricular Tachycardia^
|
|
| AAE | ;;115^Active Infection Requiring Antibiotics^
|
|
| AAD | ;;114^Renal Impairment (Serum Creatinine >1.5)^
|
|
| AAG | ;;117^Pneumonia^
|
|
| AAF | ;;116^Bleeding/Transfusions^
|
|
| DJ | ;;40^Pulmonary Fibrosis^
|
|
| DH | ;;48^Donor ABO Blood Type^
|
|
| DI | ;;49^Donor CMV^
|
|
| DF | ;;46^Donor Age^
|
|
| DG | ;;47^Biliary Stricture^
|
|
| DD | ;;44^Donor Race^
|
|
| DE | ;;45^Donor Gender^
|
|
| DB | ;;42^Renal Cancer^
|
|
| DC | ;;43^Sarcoidosis^
|
|
| DA | ;;41^Pulmonary Hypertension^
|
|
| AEI | ;;159^Valvular Cardiomyopathy^
|
|
| AEH | ;;158^Alcoholic Cardiomyopathy^
|
|
| AIG | ;;197^Plasmapheresis^
|
|
| AIA | ;;191^Renal Failure Requiring Dialysis^
|
|
| AIC | ;;193^Operative Death^
|
|
| AIB | ;;192^Perioperative MI^
|
|
| AEJ | ;;150^Heparin Sensitivity^
|
|
| TR | ||
| ABC | ;;123^Superficial Incisional SSI^
|
|
| AGA | ;;171^Current Smoker^
|
|
| AA | ;;11^Date Placed on Waiting List^
|
|
| ABA | ;;121^Stroke/CVA^
|
|
| AC | ;;13^Recipient HLA-A Typing^
|
|
| AB | ;;12^Recipient CMV^
|
|
| AE | ;;15^Recipient HLA-C Typing^
|
|
| AD | ;;14^Recipient HLA-B Typing^
|
|
| AG | ;;17^Recipient HLA-DR Typing^
|
|
| AF | ;;16^Recipient HLA-BW Typing^
|
|
| AI | ;;19^Transplant Comments^
|
|
| AH | ;;18^Recipient HLA-DQ Typing^
|
|
| ABJ | ;;120^Psychosis^
|
|
| AJ | ;;10^Recipient ABO Blood Type^
|
|
| ABD | ;;124^Deep Incisional SSI^
|
|
| II | ;;99^Autoimmune Hepatitis^
|
|
| IH | ;;98^Obstructive Uropathy from BPH^
|
|
| AJJ | ;;100^Cryptogenic Cirrhosis^
|
|
| IJ | ;;90^Non-Compliance (Med and Diet)^
|
|
| IA | ;;91^On Methadone^
|
|
| AJA | ;;101^Chronic Rejection^
|
|
| AJB | ;;102^Hepatic Artery Thrombosis^
|
|
| IB | ;;92^Post Transplant Prophylaxis for TB/Antimycobacterial Treatment^
|
|
| IE | ;;95^IgA Nephropathy^
|
|
| ID | ;;94^Rejection^
|
|
| IG | ;;97^Lithium Toxicity^
|
|
| IF | ;;96^Calcineurin Inhibitor Toxicity^
|
|
| ABE | ;;125^Systemic Sepsis^
|
| Name | Line Occurrences |
|---|---|
| TR | SRTPUTL4+4, SRTPUTL4+5 |
| >> | Not killed explicitly |
| * | Changed |
| ! | Killed |
| ~ | Newed |
| Name | Field # of Occurrence |
|---|---|
| >> SRDT | SRTPUTL4+5*, SRTPUTL4+6*, SRTPUTL4+7 |
| >> SRFLD | SRTPUTL4+4*, SRTPUTL4+5* |
| >> SRLR( | SRTPUTL4+5*, SRTPUTL4+6 |
| >> SRMM | SRTPUTL4+4 |
| >> SRP | TR* |
| >> SRTPP | SRTPUTL4+3, SRTPUTL4+4, SRTPUTL4+5 |
| >> SRX( | SRTPUTL4+4*, SRTPUTL4+7! |
| SRX1 | SRTPUTL4+2~ |
| SRXX | SRTPUTL4+2~ |
| >> SRYY( | SRTPUTL4+3, SRTPUTL4+4, SRTPUTL4+5 |
| >> SRZ | SRTPUTL4+3*, SRTPUTL4+4, SRTPUTL4+5, SRTPUTL4+7* |
| >> SRZ1 | SRTPUTL4+4*, SRTPUTL4+5*, SRTPUTL4+7*, TR |
| SRZZ | SRTPUTL4+2~ |
| >> X | SRTPUTL4+4*, SRTPUTL4+5*, GET* |
| Name | Field # of Occurrence |
|---|---|
| $T(@J | GET |
| $T(@SRP | SRTPUTL4+4, SRTPUTL4+5 |